| 0 (0%) | 01-19 20:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.9 |
1-year : | 52.45 |
| Resists | First : | 38.45 |
Second : | 44.9 |
| Pivot price | 33.24  |
|||
| Supports | First : | 33.08 |
Second : | 29.77 |
| MAs | MA(5) : | 34.09 |
MA(20) : | 33.71 |
| MA(100) : | 27.76 |
MA(250) : | 16.5 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 61.8 |
D(3) : | 58.1 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 42.39 | Low : | 5.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RAPT ] has closed below upper band by 23.3%. Bollinger Bands are 9.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.48 - 35.65 | 35.65 - 35.8 |
| Low: | 31.62 - 31.8 | 31.8 - 31.96 |
| Close: | 34.8 - 35.11 | 35.11 - 35.38 |
Mon, 19 Jan 2026
(RAPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wed, 14 Jan 2026
RAPT Therapeutics Showcases Ozureprubart Progress, Strengthened Outlook - TipRanks
Wed, 14 Jan 2026
RAPT Therapeutics, Inc. Announces Participation in JPM Healthcare Conference - TradingView — Track All Markets
Fri, 09 Jan 2026
Piper Sandler initiates coverage on Rapt Therapeutics stock with Overweight rating - Investing.com
Wed, 07 Jan 2026
RAPT Therapeutics to Present Company Overview at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Wed, 07 Jan 2026
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 28 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 65.3 (%) |
| Shares Short | 916 (K) |
| Shares Short P.Month | 1,090 (K) |
| EPS | -11.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.4 % |
| Return on Equity (ttm) | -85.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -3.02 |
| PEG Ratio | 0 |
| Price to Book value | 3.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|